September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
Oral GLP-1 Agonist Orforglipron Leads to ~15% Mean Body Weight Reduction in Adults with Overweight/Obesity
ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.
SURMOUNT-2: Tirzepatide Treatment Leads to Average 15% Weight Loss in Adults with T2D, Obesity
ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.
Global Diabetes Prevalence Will Double by 2050, Affecting 1.3 Billion People: New Predictions
Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.
“Triagonist” Therapy for Type 2 Diabetes and Comorbidities to be Previewed at 2023 ADA Scientific Sessions
ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.
SGLT-2 Inhibitor HF, CV Benefit Found Consistent Across Populations with T2D, CKD, HF
SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
Obesity & Type 2 Diabetes: Early Intervention Critical in Reducing Risk for Complications
Early intervention is important to reduce the risk for complications for patients with obesity and type 2 diabetes. Two obesity experts explain more, here.
Empagliflozin and Empagliflozin/Metformin Win FDA Approval for Pediatric Type 2 Diabetes
The 2 SGLT-2 inhibitor-based medications are the first in the class to be approved for pediatric T2D and provide a much needed additional oral treatment option for the population.
Daily Dose: Cardiovascular Safety of Testosterone-Replacement Therapy in Men with Hypogonadism
Your daily dose of clinical news you may have missed.
Testosterone Replacement Does Not Increase Risk for CV Events in Men with Hypogonadism, New Study Finds
ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.
Polycystic Ovary Syndrome Associated with Higher Mortality Risk, According to New Research
ENDO 2023. Women with PCOS face an increased risk of mortality, particularly death due to cardiovascular disease and diabetes, compared with those without PCOS.
Daily Dose: Bempedoic Acid Found Comparable to Statins for Lowering LDL-C
Take-Home Thoughts for Managing Diabetes
Eden Miller, DO, shares key takeaways on how personalized treatment helps in the management of diabetes.
Evaluating the Role of Real-World Evidence Studies
Elizabeth Holt, MD, FACE, and Eden Miller, DO, comment on the pros and cons of real-world data studies, looking particularly at the study of the OneTouch Verio Flex meter and the OneTouch Reveal apps.
Implementing the OneTouch Verio Flex® Meter and OneTouch Reveal® Mobile Application
Experts discuss steps to introduce the OneTouch Verio Flex meter and the OneTouch Reveal app to patients to better manage diabetes.
Early Time-restricted Feeding Regimen Improves Glycemic Variability, Time in Range in Patients with Prediabetes, Obesity
ENDO 2023. The pattern of intermittent fasting improved glycemic measures in a weight-independent fashion after just 7 days, according to the study abstract.
Finerenone Reduces CKD-associated Composite Cardiovascular Risk in a New Subanalysis of FIDELITY Trial
Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.
The Impact of Ozempic in the US: 3 Takeaways from a Recent Survey
Nearly half of responding medical professionals said patients without T2D have asked for an Ozempic Rx and about 18% of them have provided one, avoiding significant backlash for a denial.
Daily Dose: Metformin Reduces Risk of Long COVID
Diabetes, Prediabetes, and Diabetes Duration Linked to Higher Risk of COPD, Death
Patients with diabetes had a 35% higher risk of COPD compared with those without diabetes, according to new research.
7 Questions on Managing Patients with Diabetes at High Risk of Hypoglycemia
Try this 7-question quiz on the 2023 guidelines from The Endocrine Society that focus on advances in diabetes treatment that help minimize risk of hypoglycemia.
Flash CGM Improves Time in Range, HbA1c in Patients with T2D Using Noninsulin Therapies
Mean time in range increased by ~10% and time above range decreased by 8.1% in study participants taking as few as a single antihyperglycemic medication.
Metformin Reduced Long COVID Risk by About 40% vs Placebo in a New Phase 3 Trial
More research is needed to determine whether metformin is also effective in patients with lower body mass index or with previous infection, said researchers.
Friday's 5 Quotes for Primary Care 6-9-2023
FDA fast tracks triple-threat antithrombotic, dangers of faux semaglutide online, a guide to neurologic sequelae of COVID-19, plus 2 more reviews of note.
The Impact of Self Glucose Monitoring on Diabetes Treatment Goals
Eden Miller, DO, reviews the impact the BGM and diabetes management apps have on the patient, giving clinicians a better ability to personalize treatment and empower the patient.
Importance of Amount of Time Monitoring Diabetes
Experts discuss how the amount of time a patient spends engaging with the BGM and diabetes apps will contribute to managing their diabetes.
CGM Uptake for T2D in Primary Care and Endocrinology: Rates, Correlates, Considerations
Prescriptions for continuous glucose monitoring for patients with T2D are increasing, a new study finds, and the authors report on characteristics of new CGM users.
SGLT-2 Inhibitors Linked to Reduced Risk for Wide Range of Cancers in Study from Taiwan
Reduced risk for 10 different cancers was reported among patients with diabetes treated with SGLT2 inhibitors compared with those not treated.
Daily Dose: Prediabetes, Intervening Diabetes, & Subsequent Dementia Risk
Younger Age at Diabetes Onset Associated with Higher Risk of Dementia, According to New Study
Results also showed that prediabetes is associated with dementia risk but this risk was explained by the subsequent development of diabetes.
Endocrine Society Recommendations on How to Avoid Hypoglycemia in Patients with Diabetes: A Guideline Topline
The Endocrine Society's first update on management of hypoglycemia since 2009 emphasizes the value of new technology and therapeutics in minimizing risk.